| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 11 Nov 2025 | 4 Nov 2025 |
| Fortis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/11/2025 inter alia to consider and approve Un-Audited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended September 30 2025. Pursuant to the provisions of Regulation 30, 33, 51(2) and 52 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015 (SEBI Listing Regulations), please find attached the outcome of the aboard meeting held today i.e. November 11, 2025 The relevant disclosure is attached (As Per BSE Announcement Dated on 11.11.2025) | ||
| Board Meeting | 6 Aug 2025 | 30 Jul 2025 |
| Fortis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2025 ,inter alia, to consider and approve (1)Un-audited financial results of the Company for the quarter ended June 30, 2025. (2)Alteration of rights of debenture holders/ matters affecting the rights and interests of debenture holders of the existing 1,55,000 (One lac and fifty-five thousand) listed, senior, secured, rated, redeemable Non-Convertible Debenture, each having a face value of INR 1,00,000/- (Indian Rupees One lac) and an aggregate value of up to INR 1550,00,00,000/- (Indian Rupees One Thousand Five Hundred and Fifty Crores only) Relevant disclosure is attached. (As per BSE Announcement Dated on 06/08/2025) | ||
| Board Meeting | 20 May 2025 | 8 May 2025 |
| Fortis Healthcare Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 20/05/2025 inter alia to consider and approve a) audited financial results of the Company for the quarter and financial year ended March 31 2025; and b) final dividend if any on the equity shares of the Company for the financial year ended March 31 2025. Pursuant to the provisions of Regulation 30, 33 and Regulation 51(2) and 52 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirement) Regulation, 2015 (SEBI Listing Regulations) and the Master Circular issued by SEBI through circular number SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 as amended, please find attached the Outcome of Board meeting held on May 20, 2025. (As Per BSE Announcement Dated on :20.05.2025) | ||
| Board Meeting | 20 Mar 2025 | 20 Mar 2025 |
| Please Find enclosed disclosure for updates in policies. | ||
| Board Meeting | 7 Feb 2025 | 29 Jan 2025 |
| FORTIS HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2025 inter alia to consider and approve Un-audited financial results for the quarter and period ended December 31 2024 Outcome of Board Meeting held on February 7, 2025 (As per BSE Announcement Dated on 07/02/2025) | ||
| Board Meeting | 27 Dec 2024 | 27 Dec 2024 |
| Outcome of the Board Meeting-December 27, 2024 Relevant disclosure is attached. | ||
Fortis will take charge of the entire operational and financial aspects. Hence, consolidating the hospital's performance within its network.
Operating performance remained strong with EBITDA rising 43% year-on-year to ₹490.4 crore. The EBITDA margin expanded to 22.6%, from 18.4% a year ago.
The tax demand will not affect the company’s financials or operations, it said in a regulatory filing.
Here are some of the stocks that may see significant price movement today: UltraTech Cement, Jio Financial, Avenue Supermarts, etc.
EBITDA grew 32.1% YoY at ₹375.2 crore v/s ₹284 crore, a period to period, as was the expansion of EBITDA margin at 19.5% versus 16.9% Q3 FY24.
The deal worth ₹429.37 crore involves acquiring 5,970,149 equity shares at an agreed price of ₹719.2 per share through a shareholders' agreement.
Revenue from operations saw a notable growth of 12.3%, reaching ₹1,988.4 Crore, compared to ₹1,770 Crore YoY.
Jacob Ballas and International Finance Corporation (IFC), who together with Resurgence PE own approximately 34% of the diagnostics company.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
